TM Owner Pfizer
Mektovi 15mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Mektovi 15 mg tablets contain binimetinib, a MEK inhibitor targeted cancer medicine.
- Mektovi has no approved use as a single agent; it is approved only for use in combination with the BRAF inhibitor encorafenib (Braftovi), never alone, for two indications: unresectable or metastatic melanoma with a BRAF V600E or V600K mutation confirmed by an FDA-approved test, and, more recently, metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation in adults.
- The usual regimen is Mektovi 45 mg (three 15 mg tablets) twice daily, taken with encorafenib once daily.
- Mektovi has not been established as safe and effective in children.
- This product row lists only Mektovi; a corresponding Braftovi (encorafenib) prescription is required alongside it, and this should never be filled or taken as a stand-alone therapy.
Side Effects
- In melanoma patients, the most common effects (25% or more) are fatigue, nausea, diarrhea, vomiting, and abdominal pain; in lung cancer patients, fatigue, nausea, diarrhea, muscle or joint pain, and visual disturbances are also frequent.
- Mektovi carries several serious risks: new skin and other cancers, weakened heart pumping ability (cardiomyopathy, requiring baseline and periodic heart-function tests), blood clots, eye problems including serous retinopathy and retinal vein occlusion, lung inflammation, liver injury, muscle breakdown (rhabdomyolysis), and serious bleeding.
- There is no boxed warning on the current label, but these are highlighted warnings and precautions.
- Seek urgent care for sudden vision changes, unexplained muscle pain or weakness, breathlessness, yellowing of the skin or eyes, or unusual bleeding.
Precautions & Warnings
- There are no formal contraindications to Mektovi, but it requires regular monitoring: an eye examination and heart function (ejection fraction) test at baseline and periodically during treatment, and liver function tests as directed.
- Mektovi can cause fetal harm; women of reproductive potential must use effective contraception during treatment and for 30 days after the last dose, and breastfeeding should be avoided during treatment and for 3 days afterward.
- In moderate-to-severe liver (hepatic) impairment, a reduced dose of 30 mg twice daily is used.
- Mektovi tablets can be taken with or without food.
- Because it is always used together with encorafenib, follow the combined dosing schedule carefully and never adjust one medicine without the other unless instructed by your oncology team.
Avoid Interactions
- No clinically important pharmacokinetic drug interactions have been identified for binimetinib itself, but Mektovi is always taken together with encorafenib, which does have significant interactions, including strong CYP3A4 inhibitors and inducers; your oncology team manages these as part of the combined regimen.
- Because Mektovi and encorafenib together can affect the heart and liver, other medicines that also affect heart rhythm (QT-prolonging drugs) or liver function should be reviewed carefully by your healthcare provider before starting or continuing treatment.
- Live vaccines should be discussed with your provider before use during treatment.
- Always give your healthcare provider and pharmacist a complete list of all prescription medicines, over-the-counter products, and supplements, including the encorafenib (Braftovi) you take alongside Mektovi, so interactions between all agents can be checked together.
References
Frequently Asked Questions
Mektovi (binimetinib) treats BRAF V600E/K-mutant metastatic melanoma and BRAF V600E-mutant metastatic lung cancer, always combined with encorafenib (Braftovi). Mektovi has no approved use on its own. It works by blocking a growth signal (MEK) that BRAF-mutant tumor cells rely on.
The usual dose is 45 mg (three 15 mg tablets) by mouth twice daily, about 12 hours apart, taken with or without food, together with once-daily encorafenib. Swallow tablets whole. Never take Mektovi without its paired medicine, encorafenib.
Fatigue, nausea, diarrhea, vomiting, and abdominal pain are common. Serious risks include heart, eye, and liver problems, blood clots, and muscle breakdown. Report sudden vision changes, unexplained muscle pain, or yellowing skin or eyes to your healthcare provider right away.
Avoid pregnancy — use effective contraception during treatment and for 30 days after stopping, and avoid breastfeeding for 3 days after the last dose. No major food or drug interactions are known for binimetinib itself, but tell your provider about all medicines, since it is always combined with encorafenib.
Yes. Your healthcare provider will check your heart function and eyes before starting Mektovi and periodically during treatment, plus liver blood tests. This monitoring helps catch cardiomyopathy, retinal problems, or liver injury early, while they are still manageable.
No. Mektovi is only approved and effective when combined with encorafenib (Braftovi); there is no approved single-agent use. If you have only a Mektovi prescription and not encorafenib, check with your oncology team before starting treatment.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
